The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.00
Bid: 1,766.00
Ask: 1,767.00
Change: 32.50 (1.87%)
Spread: 1.00 (0.057%)
Open: 1,736.00
High: 1,766.50
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks erase losses after Spanish auction

Tue, 28th Aug 2012 11:47

- Spanish bond auction lifts sentiment- Miners lower on concerns over Japan- Chemring drops profit warning.London's blue-chip index was trading broadly flat by midday, having erased all of the morning's losses, after a solid Spanish bond auction eased concerns about the heavily indebted Eurozone country.Miners were providing a drag on the FTSE 100 this morning on concerns about Japan, the world's third-largest economy. The Japanese government has reduced its view on personal consumption, housing construction, exports, imports and industrial output for the first 10 months of the year. "The Japanese economy is on the way to recovery at a moderate pace, partly due to reconstruction demand, while some weak movements are seen recently," the Cabinet Office said in its monthly report. JPMorgan Securities Japan and BNP Paribas are forecasting a 0.3% and 0.9% decline in third-quarter Japanese gross domestic product (GDP), respectively.Turning to Spain, the Treasury raised €3.607bn in short-term debt this morning, above the top-end of its target rage of €2.5-3.5bn. Borrowing costs dropped dramatically and demand increased significantly compared with the previous auction in July. According to the country's national statistics institute, Spanish GDP declined at a 1.3% annual rate in the second quarter, compared with the initial estimate of a 1% contraction. Markets continue to wait official news from the European Central Bank (ECB) regarding its proposed bond-buying programme. However, analyst Craig Erlam from Alpari said that recent market chatter has shown some consistency: "There have been numerous reports recently that claim to have inside knowledge on the matter. While they all differ slightly, there is also a lot of consistency. Based on these reports, it looks likely that the ECB will target short term debt yields, which will include a non-fixed yield cap on Spanish and Italian bonds," he said.However, ECB member Jörg Asmussen has said over the weekend that the EFSF bailout fund must take the lead in the purchase of any sovereign debt before the ECB steps in. "The ECB council will continue to decide in full independence whether, when and how it will purchase bonds on the secondary market," he said.FTSE 100: Kingfisher, G4S and miners weigh on benchmark indexB&Q owner Kingfisher was the heaviest faller of the day after Bank of America Merrill Lunch downgraded its rating on the stock to 'underperform'. Security giant G4S fell after expressing disappointment over the problems related to its Olympics contract, saying that it will incur a £50m loss on the contract in the first half. Meanwhile, the company said that a restructuring of its overhead structure will lead the loss of 1,100 jobs. Nevertheless, the firm revealed that turnover at constant exchange rates rose 7.5% while profits were flat. Miners were firmly out of favour this morning on concerns over the Japanese economy. BHP Billiton fell after announcing the sale of its Yeelirrie uranium deposit in Western Australia to Cameco for $430m. BHP and sector peers ENRC, Kazakhmys and Vedanta were also lower after Morgan Stanley reduced its target price for all four stocks. Drugs giant AstraZeneca was lower after saying that it has appointed Roche's Chief Operating Officer as its new Chief Executive Officer. Meanwhile, the firm also announced that the European Commission has granted marketing authorisation to its ZINFORO treatment. Sector peer GlaxoSmithKline was suffering from a downgrade by UBS.Bunzl, the international distribution and outsourcing group, fell despite saying that pre-tax profits and revenues in the first half rose 9% and 7%, respectively. FTSE 250: Chemring drops after profit warningDefence contractor Chemring dropped after it issued a profits warning, saying a computer glitch and production delays are likely to wipe £15m off full-year earnings as it considers a takeover offer from private equity giant Carlyle.Heading the other way was chemicals group Yule Catto after reporting a pre-tax profit of £56m in the first half, up from £52.4m the year before. Sales, however, fell to £603.3m from £664.3m.FTSE 100 - RisersITV (ITV) 85.00p +1.74%Carnival (CCL) 2,128.00p +1.72%Barclays (BARC) 190.20p +1.60%CRH (CRH) 1,149.00p +1.59%Fresnillo (FRES) 1,606.00p +1.52%Capital Shopping Centres Group (CSCG) 332.90p +1.22%United Utilities Group (UU.) 719.50p +1.20%BT Group (BT.A) 217.50p +1.07%Sainsbury (J) (SBRY) 332.60p +0.94%Glencore International (GLEN) 370.00p +0.86%FTSE 100 - FallersKingfisher (KGF) 275.60p -3.54%Evraz (EVR) 239.70p -2.88%Kazakhmys (KAZ) 642.00p -2.80%G4S (GFS) 259.10p -2.67%Eurasian Natural Resources Corp. (ENRC) 330.50p -2.48%Bunzl (BNZL) 1,084.00p -2.43%Vedanta Resources (VED) 906.00p -2.00%Marks & Spencer Group (MKS) 364.30p -1.99%IMI (IMI) 840.50p -1.93%InterContinental Hotels Group (IHG) 1,587.00p -1.79%FTSE 250 - RisersYule Catto & Co (YULC) 152.80p +7.76%Moneysupermarket.com Group (MONY) 138.10p +5.42%Ted Baker (TED) 1,000.00p +3.41%Renishaw (RSW) 1,568.00p +2.55%Dialight (DIA) 1,099.00p +2.33%Imagination Technologies Group (IMG) 578.50p +2.12%Home Retail Group (HOME) 95.15p +2.04%Homeserve (HSV) 216.30p +1.93%St. Modwen Properties (SMP) 202.40p +1.71%COLT Group SA (COLT) 119.20p +1.71%FTSE 250 - FallersChemring Group (CHG) 324.00p -12.55%Bumi (BUMI) 335.30p -5.55%Heritage Oil (HOIL) 191.00p -4.45%Cairn Energy (CNE) 285.10p -3.78%BTG (BTG) 310.30p -2.64%Afren (AFR) 126.80p -2.39%Cape (CIU) 188.50p -2.38%Bwin.party Digital Entertainment (BPTY) 92.90p -2.26%Perform Group (PER) 372.00p -2.11%NMC Health (NMC) 193.00p -2.03%BC
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.